Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

The U.S.'s drug regulator has approved Roche's Susvimo drug for the treatment of diabetic macular edema, the leading cause of diabetes-related blindness, the pharmaceutical company said.

Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...

Genentech unit has received FDA approval for its drug Susvimo 100 mg/mL injection for the treatment of diabetic macular edema, a leading cause of blindness for people with diabetes. Susvimo, also ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

LateralCare is proud to unveil revenue alai, the next evolution of its flagship product, alai. This bold rebrand underscores the company's unwavering commitment to cutting-edge AI-driven revenue cycle ...

Black Tech Jobs, a platform dedicated to connecting underrepresented talent with tech opportunities, and Blueprint Technologies, a leader in data intelligence solutions, are proud to announce NueTech, ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...